✦ LIBER ✦

Designing antibodies for human therapies

✍ Scribed by MAGE, ROSE G.

Book ID: 109754676
Publisher: Nature Publishing Group
Year: 1988
Tongue: English
Weight: 275 KB
Volume: 333
Category: Article
ISSN: 0028-0836
DOI: 10.1038/333807c0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-CD3-based bispecific antibody desig

Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms

✍ Brian K. Link; Sheri A. Kostelny; Michael S. Cole; William P. Fusselman; J. Yun 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 107 KB 👁 2 views

## Anti -CD3 ؋ anti-B-cell antigen bispecific monoclonal antibodies (bsAbs) can redirect T-cell-mediated lysis toward malignant B cells. Clinical trials with CD3-based bsAbs have shown toxicity in patients which is likely related to nonspecific T-cell activation and targeting. Our current studies

Humanized antibodies for therapy

✍ Co, Man Sung; Queen, Cary 📂 Article 📅 1991 🏛 Nature Publishing Group 🌐 English ⚖ 249 KB

Designing rational therapies for multipl

Designing rational therapies for multiple sclerosis

✍ Steinman, Lawrence ;Conlon, Paul 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 388 KB

Reshaping human antibodies for therapy

✍ Riechmann, Lutz; Clark, Michael; Waldmann, Herman; Winter, Greg 📂 Article 📅 1988 🏛 Nature Publishing Group 🌐 English ⚖ 535 KB

Human antibodies by design

✍ Vaughan, Tristan J.; Osbourn, Jane K.; Tempest, Philip R. 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 824 KB

Chimeric immunoligand containing interle

Chimeric immunoligand containing interleukin-2 receptor binding sequence; human recombinant interleukin-2 and antibody constant region fusion protein construction using plasmid pIL-2IgG1 for e.g. leukemia and automimmune disease therapy and recombinant vaccine: Protein Design Labs USA 5349 053; 20 September 1994

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 174 KB